Guide contents
Open in calculatorCompound briefing
AOD9604 is a modified fragment of the C-terminal region (amino acids 176–191) of human growth hormone (hGH), with an added disulphide bridge to enhance stability. Originally developed as an anti-obesity agent at Monash University, it isolates the fat-mobilising activity of hGH without the growth-promoting, insulin-resistance or IGF-1-elevating effects of the full hormone. It has progressed through Phase 2 clinical trials for obesity and is also studied for cartilage repair and metabolic applications.
The research question
AOD9604 was designed to investigate fat metabolism without engaging the full growth-hormone receptor programme. The important distinction is not simply whether lipolysis changes in a model, but whether a durable and clinically meaningful outcome follows.
Mechanism & research themes
Stimulates lipolysis (breakdown of stored triglycerides) and inhibits lipogenesis (formation of new adipose tissue) via mechanisms distinct from the GH receptor — believed to involve β3-adrenergic receptor pathways in adipose tissue. Does not bind the GH receptor, so it does not elevate IGF-1, impair glucose tolerance or stimulate skeletal growth.
Targeted lipolysis in adipose tissue without GH-receptor activation
No elevation of IGF-1, blood glucose or insulin resistance in trials
Phase 2 data showing favourable body-composition shifts
Investigational support for cartilage repair and osteoarthritis research
Favourable safety profile across human trials to date
Compatible with GLP-1 / metabolic peptide protocols in research stacks
These are research themes reported across the literature, not established benefits or indications.
Evidence assessment
Human obesity studies have not produced the magnitude or consistency of effect seen with later incretin-based treatments. Mechanistic rationale is stronger than the established efficacy case.
What to look for
Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.
What not to assume
A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.
Protocol literature
Commonly referenced research protocols use 250–500mcg subcutaneously once daily, typically administered in a fasted morning state to align with peak lipolytic activity. Cycles often run 8–12 weeks. Higher 500mcg–1mg daily doses are reported in obesity-focused research.
Reported persistence
Plasma half-life approximately 30 minutes; biological activity on adipocytes persists longer through downstream signalling.
Calculator starting point
0.3 mg per reference dose
6 doses per week · 12-week cycle
2 mL default reconstitution volume
300 mcg/day SC, typically morning fasted.
Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.
Calculate AOD9604Laboratory handling
Reconstitution reference
Reconstitute a 5mg vial with 1–2mL bacteriostatic water for a 2.5–5mg/mL working concentration. Swirl gently down the side of the vial — do not shake.
Storage reference
Lyophilised: 2–8°C, stable approximately 24 months; avoid freeze-thaw cycles. Reconstituted: 2–8°C, protect from light, use within 30 days.
Minimum documentation standard
- Record the lot identifier and review its matching analytical documentation.
- Use aseptic technique and record diluent, final volume and calculated concentration.
- Label preparation date, storage conditions and any light or freeze–thaw restrictions.
- Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Limitations & safety
Magnitude of weight loss in human trials has been modest compared with GLP-1-class agents.
Most efficacy data sits at Phase 2; no Phase 3 obesity approval has been completed.
Mild injection-site reactions reported; long-term safety data beyond trial durations remains limited.
Research use only
This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.
Continue reading